The amalgamation is expected to create a future-ready, diversified CDMO platform with a technology-led focus across three high-growth verticals-Antibody Drug Conjugates
Lonza’s new simplified and streamlined operating model is designed to support its One Lonza vision and strategy
The inspection, conducted from March 17 to March 21, 2025, concluded with one observation in Form 483
Company expects to begin building four more domestic manufacturing sites this year and add 13,000 high-wage manufacturing and construction jobs in America
Eleven CRDMOs collaborate to form IPSO with the aim to elevate India’s position in the global pharmaceutical value-chain
We will continue to expand our range of purified excipients, offering pharmaceutical companies a dependable partner
The company is committed to revolutionizing API development by advancing synthesis and analytical processes that enhance quality and impact lives
Groundbreaking collaboration harnesses AI-driven insights and advanced manufacturing to create next-generation adjuvants for emerging biological threats
The company ensures a reliable and strong portfolio at competitive prices without compromising on excellent quality
Regulatory filings underway for a third indication for darolutamide in prostate cancer, for finerenone in a common form of heart failure, and acoramidis in transthyretin amyloid
Subscribe To Our Newsletter & Stay Updated
